American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder FREMONT, CA, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical-stage biopharmaceutical company developing...

American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD Patient enrollment has been completed for a Phase II Part I clinical trial at the University of California, San Francisco (UCSF) Medical Center Primary objective of Phase II Part I clinical trial is...

American BriVision Announces Two Financial Transactions to Improve Working Capital and Reduce Debt FREMONT, CA, April 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – American BriVision (Holding) Corporation (OTCQB: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions...

American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) PDC-1421, the active ingredient of ABV-1505, is being expanded into Adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) A site monitoring visit for the...

American BriVision Announces Effectiveness of Form S-1 Registration Statement FREMONT, CA, Aug. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – American BriVision (Holding) Corporation (OTCQB: ABVC) (the “Company”), a clinical stage biopharmaceutical company developing...